Featuring perspectives from Dr Naveen Pemmaraju, including the following topics: Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00) Updated data with navitoclax i

Featuring a slide presentation and related discussion from Dr Kanwal Raghav, including the following topics: Prevalence of HER2 alterations among patients with advanced gastrointestinal tumors beyond

Featuring an interview with Dr Kanwal Raghav, including the following topics: Activity and tolerability of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing colorectal cancer (CRC) (0:0

Featuring perspectives from Dr Bita Fakhri, including the following topics: Overview of select presentations from ASH 2023; recent FDA approval of lisocabtagene maraleucel (0:00) 6-year follow-up fro

Featuring perspectives from Prof Thierry Andr and Dr Arvind Dasari, including the following topics: Introduction: Year in Review on the Ground (0:00) Treatment of HER2-Positive Colorectal Cancer (CR

Featuring perspectives from Dr Shilpa Gupta and Prof Thomas Powles, including the following topics: Introduction: The Cancer-Immunity Cycle (0:00) Nonmetastatic Urothelial Bladder Cancer Dr Gupta (

Featuring a slide presentation and related discussion from Dr Manish Patel, including the following topics: Pharmacology of B7-H3 and role in tumor pathogenesis (0:00) Current and future clinical dev

Featuring perspectives from Dr Manish Patel, including the following topics: Insights into a comprehensive clinical research practice (0:00) Transformation of the conduct and design of clinical trial

Featuring perspectives from Dr Robin (Katie) Kelley and Dr Mark Yarchoan, including the following topics: Introduction: Interdisciplinary Management of Hepatocellular Carcinoma (HCC) in the Communit

Featuring perspectives from Dr Melissa Johnson, including the following topics: Role of biomarker testing in optimal selection of first-line therapy for patients with non-small cell lung cancer (NSCL